Cholangiocarcinoma Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight | Incyte, Agios Pharmaceuticals, Servier Pharmaceuticals, Taiho Pharma, Astrazeneca, Decalth Systems, Basilea Pharmaceuticals, Taiho Oncol

DelveInsight's "Cholangiocarcinoma Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of Cholangiocarcinoma, historical and forecasted epidemiology as well as the Cholangiocarcinoma market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Discover which therapies are expected to grab the Cholangiocarcinoma Market Share @ Cholangiocarcinoma Market Outlook- https://www.delveinsight.com/sample-request/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Cholangiocarcinoma Market Report
• In March 2025, Lisata Therapeutics, Inc. announced a clinical trial study is to test a new drug plus standard treatment compared with standard treatment alone in patients with previously untreated cholangiocarcinoma or those that have progressed after first-line treatment for cholangiocarcinoma.
• In March 2025, AstraZeneca conducted a study to assess the efficacy and tolerability of rilvegostomig compared to placebo in combination with investigator's choice of chemotherapy in participants with BTC after surgical resection with curative intent.
• In March 2025, Hoffmann-La Roche organized an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion.
• As per DelveInsight's estimates, the total incident cases of cholangiocarcinoma in the United States were ~14,000 in 2023.
• In the United States, out of all the cholangiocarcinoma cases, intrahepatic cancer accounted were around 6000.
• It is observed that cholangiocarcinoma occurs majorly in the age group of 70-79 years.
• The increase in Cholangiocarcinoma Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
• As per DelveInsight analysis, the Cholangiocarcinoma Market is anticipated to witness growth at a considerable CAGR.
• The leading Cholangiocarcinoma Companies such as Incyte, Agios Pharmaceuticals, Servier Pharmaceuticals, Taiho Pharma, Astrazeneca, Decalth Systems, Basilea Pharmaceuticals, Taiho Oncology, Eisai Pharmaceuticals, TransThera Sciences (Nanjing), Inc., and others.
• Promising Cholangiocarcinoma Pipeline Therapies such as PEMAZYRE (pemigatinib), TIBSOVO (ivosidenib), LYTGOBI (futibatinib), Imfinzi (durvalumab), Melphalan, Derazantinib, Futibatinib (TAS-120), E7090, TT-0040, and others

Stay ahead in the Cholangiocarcinoma Therapeutics Market with DelveInsight's Strategic Report @ Cholangiocarcinoma Market Outlook- https://www.delveinsight.com/sample-request/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Cholangiocarcinoma Epidemiology Segmentation in the 7MM
• Total Prevalence of Cholangiocarcinoma
• Prevalent Cases of Cholangiocarcinoma by severity
• Gender-specific Prevalence of Cholangiocarcinoma
• Diagnosed Cases of Episodic and Chronic Cholangiocarcinoma

Download the report to understand which factors are driving Cholangiocarcinoma Epidemiology trends @ Cholangiocarcinoma Prevalence- https://www.delveinsight.com/sample-request/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Cholangiocarcinoma Marketed Drugs
• PEMAZYRE (pemigatinib): Incyte
PEMAZYRE is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. Recommended dosage is 13.5 mg orally once daily for 14 consecutive days, followed by 7 days of therapy in 21-day cycles. Continue treatment until disease progression or unacceptable toxicity occurs. It has been granted Breakthrough designation, and Orphan Drug Designation and was given a priority review for the treatment of adults with previously treated, unresectable, locally advanced, or metastatic cholangiocarcinoma.

• TIBSOVO (ivosidenib): Agios Pharmaceuticals/Servier Pharmaceuticals
TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test, for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated. The recommended dosage of TIBSOVO is 500 mg taken orally once daily until disease progression or unacceptable toxicity. It has been granted orphan drug designation and fast-track Designation by the US FDA and orphan designation by the European Commission.

Cholangiocarcinoma Emerging Drugs
• Tinengotinib: TransThera Sciences
Tinengotinib is an innovative, global Phase III stage spectrum-selective kinase inhibitor that exerts antitumor effects by targeting tumor cells and improving the tumor microenvironment. Ongoing clinical trials in the US and China have revealed the potential of Tinengotinib to be efficacious in various solid tumors.

• Silmitasertib (CX-4945): Senhwa Biosciences
Silmitasertib (CX-4945), a synthetically derived small molecule, is provided as a sodium salt in hard gelatin capsule shells with oral administration. CK2 (Casein kinase 2) is a protein kinase that has elevated activity in many cancers and has a direct role in DNA damage repair. The DNA repair pathways enable tumor cells to survive damage induced by treatment with chemotherapeutic agents. Inhibitors of DNA repair pathways have been shown to increase the efficacy of DNA-damaging chemotherapeutic drugs when these are used in combination.

Cholangiocarcinoma Treatment Market Landscape
The Cholangiocarcinoma treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Cholangiocarcinoma has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

Cholangiocarcinoma Therapies and Companies
• PEMAZYRE (pemigatinib): Incyte
• TIBSOVO (ivosidenib): Agios Pharmaceuticals/Servier Pharmaceutical
• LYTGOBI (futibatinib): Taiho Pharma
• Imfinzi (durvalumab): Astrazeneca
• Melphalan: Decalth Systems
• Derazantinib: Basilea Pharmaceuticals
• Futibatinib (TAS-120): Taiho Oncology
• E7090: Eisai Pharmaceuticals
• TT-0040: TransThera Sciences (Nanjing), Inc.

To learn more about Cholangiocarcinoma treatment guidelines, visit @ Cholangiocarcinoma Treatment Market Landscape- https://www.delveinsight.com/sample-request/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Cholangiocarcinoma Market Outlook
The report's outlook on the Cholangiocarcinoma market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Cholangiocarcinoma therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Cholangiocarcinoma drug and late-stage pipeline therapy.

Cholangiocarcinoma Drugs Uptake
The drug chapter of the Cholangiocarcinoma report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Cholangiocarcinoma.

Major Cholangiocarcinoma Companies
Incyte, Agios Pharmaceuticals, Servier Pharmaceuticals, Taiho Pharma, Astrazeneca, Decalth Systems, Basilea Pharmaceuticals, Taiho Oncology, Eisai Pharmaceuticals, TransThera Sciences (Nanjing), Inc., and others

Learn more about the FDA-approved drugs for Cholangiocarcinoma @ Drugs for Cholangiocarcinoma Treatment- https://www.delveinsight.com/sample-request/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Cholangiocarcinoma Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Cholangiocarcinoma Companies- Incyte, Agios Pharmaceuticals, Servier Pharmaceuticals, Taiho Pharma, Astrazeneca, Decalth Systems, Basilea Pharmaceuticals, Taiho Oncology, Eisai Pharmaceuticals, TransThera Sciences (Nanjing), Inc., and others
• Cholangiocarcinoma Pipeline Therapies- PEMAZYRE (pemigatinib), TIBSOVO (ivosidenib), LYTGOBI (futibatinib), Imfinzi (durvalumab), Melphalan, Derazantinib, Futibatinib (TAS-120), E7090, TT-0040, and others
• Cholangiocarcinoma Market Dynamics: Cholangiocarcinoma Market Drivers and Barriers
• Cholangiocarcinoma Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Cholangiocarcinoma Drugs in development @ Cholangiocarcinoma Clinical Trials Assessment- https://www.delveinsight.com/sample-request/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1 Key Insights
2 Cholangiocarcinoma Report Introduction
3 Cholangiocarcinoma Executive Summary
4 Key Events
5 Cholangiocarcinoma Market Overview at a Glance
6 Cholangiocarcinoma Market Disease Background and Overview
7 Current Cholangiocarcinoma Treatment Practices
8 Guidelines: Diagnosis and Treatment
9 Epidemiology and Market Forecast Methodology
10 Epidemiology and Patient Population
11 Cholangiocarcinoma Patient Journey
12 Cholangiocarcinoma Marketed Therapies
13 Cholangiocarcinoma Emerging Therapies
14 Cholangiocarcinoma (CCA): Market Analysis
15 Unmet Needs
16 SWOT Analysis
17 KOL Views
18 Cholangiocarcinoma Market Access and Reimbursement
19 Cholangiocarcinoma Market Access and Reimbursement: CCA
20 Appendix
21 DelveInsight Capabilities
22 Disclaimer
23 About DelveInsight

List of Top Selling Market Research Reports in 2025

Biopsy devices market- https://www.delveinsight.com/report-store/biopsy-devices-market
Diabetic wound market - https://www.delveinsight.com/report-store/diabetic-wounds-market
Joint reconstruction devices market- https://www.delveinsight.com/report-store/joint-reconstruction-devices-market
Pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services
Spinal implants market- https://www.delveinsight.com/report-store/spinal-implants-market
Attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Cystic fibrosis market- https://www.delveinsight.com/report-store/cystic-fibrosis-market
Heart failure market- https://www.delveinsight.com/report-store/congestive-heart-failure-market
NK Cell therapy market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
Positive airway pressure device market - https://www.delveinsight.com/report-store/positive-airway-pressure-device-market
Stem cell market- https://www.delveinsight.com/report-store/stem-cell-market
Surgical sealant market- https://www.delveinsight.com/report-store/surgical-sealant-tissue-patch-market
Thyroid cancer market- https://www.delveinsight.com/report-store/thyroid-cancer-market
Urinary catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
Intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
Uterine fibroids market- https://www.delveinsight.com/report-store/uterine-leiomyoma-uterine-fibroids-market
Attention deficit hyperactivity disorder adhd market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Lice infestations market- https://www.delveinsight.com/report-store/lice-infestations-market
Lymphoedema market- https://www.delveinsight.com/report-store/lymphoedema-market
Dyspepsia market- https://www.delveinsight.com/report-store/functional-dyspepsia-pipeline-insight
Antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/

This release was published on openPR.